z-logo
open-access-imgOpen Access
Genetic variants in PI 3K/ AKT pathway are associated with severe radiation pneumonitis in lung cancer patients treated with radiation therapy
Author(s) -
Tang Yang,
Liu Bo,
Li Jing,
Wu Huanlei,
Yang Ju,
Zhou Xiao,
Yi Mingxiao,
Li Qianxia,
Yu Shiying,
Yuan Xianglin
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.564
Subject(s) - lung cancer , genotype , medicine , protein kinase b , radiation therapy , hazard ratio , pneumonitis , gastroenterology , proportional hazards model , oncology , cancer , population , radiation pneumonitis , lung , biology , apoptosis , genetics , gene , confidence interval , environmental health
PI 3K/ AKT pathway plays important roles in inflammatory and fibrotic diseases while its connection to radiation pneumonitis ( RP ) is unclear. In this study, we explored the associations of genetic variants in PI 3K/ AKT pathway with RP in lung cancer patients with radiotherapy. Two hundred and sixty one lung cancer patients with radiotherapy were included in this prospective study ( NCT 02490319) and genotyped by MassArray and Sanger Sequence methods. By multivariate Cox hazard analysis and multiple testing, GA / GG genotype of AKT 2 : rs33933140 ( HR  = 0.272, 95% CI : 0.140–0.530, P  =   1.3E–4, P c  = 9.1E–4), and the GT / GG genotype of PI 3 CA : rs9838117 ( HR  = 0.132, 95% CI : 0.042–0.416, P  =   0.001, P c  = 0.006) were found to be strongly associated with a decreased occurrence of RP  ≥ grade 3. And patients with the CT / TT genotype of AKT 2 : rs11880261 had a notably higher incidence of RP  ≥ grade 3 ( HR  = 2.950, 95% CI : 1.380–6.305, P  =   0.005, P c  = 0.025). We concluded that the genetic variants of PI 3K/ AKT pathway were significantly related to RP of grade ≥ 3 and may thus be predictors of severe RP before radiotherapy, if further validated in larger population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here